

Ziming Du

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1235179/publications.pdf>

Version: 2024-02-01

17
papers

664
citations

840776

11
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1425
citing authors

#	ARTICLE	IF	CITATIONS
1	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	1.2	4
2	ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	10
3	Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of <i>NTRK1</i> . <i>JCO Precision Oncology</i> , 2020, 4, 79-90.	3.0	27
4	Qualifying antibodies for image-based immune profiling and multiplexed tissue imaging. <i>Nature Protocols</i> , 2019, 14, 2900-2930.	12.0	92
5	Highly multiplexed immunofluorescence images and single-cell data of immune markers in tonsil and lung cancer. <i>Scientific Data</i> , 2019, 6, 323.	5.3	39
6	Molecular characterization and management of secondary resistance to serial TRK inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22547-e22547.	1.6	1
7	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	1.2	67
8	Meningioma transcription factors link cell lineage with systemic metabolic cues. <i>Neuro-Oncology</i> , 2018, 20, 1331-1343.	1.2	9
9	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	35
10	CRAN-11. MULTIPLEXED IMMUNOFLUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i39.	1.2	2
11	Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. <i>Cell Communication and Signaling</i> , 2017, 15, 34.	6.5	21
12	Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. <i>Oncotarget</i> , 2016, 7, 76565-76576.	1.8	100
13	Decreased <i>FOXJ1</i> expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. <i>Journal of Pathology</i> , 2016, 238, 584-597.	4.5	29
14	Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. <i>Modern Pathology</i> , 2016, 29, 1446-1459.	5.5	15
15	Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. <i>Oncotarget</i> , 2016, 7, 30230-30240.	1.8	13
16	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	1.8	127
17	ARID1A and TERT promoter mutations in dedifferentiated meningioma. <i>Cancer Genetics</i> , 2015, 208, 345-350.	0.4	73